DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trial
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2018
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GMMG-DANTE
- 14 Jan 2018 Last checked against European Clinical Trials Database record.
- 12 Jan 2017 Status changed from not yet recruiting to recruiting.
- 17 Nov 2016 New trial record